Corma-Gómez, AnaïsFernández Fuertes, MartaGarcía, EstefaníaFuentes López, AnaGómez Ayerbe, CristinaRivero Juárez, AntonioDomínguez, CarmenSantos, MartaViñuela, LauraPalacios, RosarioReal Navarrete, Luis MiguelRivero, AntonioMacías Sánchez, JuanPineda Vergara, Juan AntonioGarcía, Federico2025-01-222025-01-222022-05-28Corma-Gómez, A., Fernández Fuertes, M., García, E., Fuentes López, A., Gómez Ayerbe, C., Rivero Juárez, A.,...,García, F. (2022). Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clinical Microbiology and Infection (CMI), 28 (11), 1492-1498. https://doi.org/10.1016/j.cmi.2022.05.018.1198-743X1469-0691https://hdl.handle.net/11441/167257Objectives The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. Methods This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Results Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts <200 cells/mm3 (64%; p < 0.001). The median log10 IgG neutralization levels were 2.4 IU/mL (Q1–Q3, 1.0–3.1) among PLWH with CD4 counts <200 cells/mm3, 3.1 IU/mL (Q1–Q3, 2.8–3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1–Q3, 2.7–3.4) for PLWH with CD4 counts ≥350 cells/mm3 (p = 0.016). In the multivariate analysis, CD4 counts ≥350 cells/mm3 (OR: 7.10; 95% CI, 1.91–26.46; p = 0.004) and receiving mRNA-vectored COVID-19 vaccines (OR: 8.19; 95% CI, 3.24–20.70; p ≤ 0.001) were independently associated with a higher probability of response to vaccination. Discussion HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts <200 cells/μL. Adenoviral-vectored vaccines should be avoided in PLWH whenever possible.application/pdf31 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/CD4 T-cell countsHumoral responsePeople living with HIVSARS-CoV-2Vaccineinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.1016/j.cmi.2022.05.018